Background: The prevalence of severe asthma among asthmatic patients is estimated between 5-10% in France. The aim of this work was to describe clinical features of patients included in the French Severe Asthma Palomb cohort.

Methods: Patients followed in a real-life context by pulmonologists located in 2 regions since 2019. Inclusion criteria: 1) ?18 years-old, 2) >6 months follow-up before inclusion for severe asthma, (GINA, 2019) 3) combination of ICS and LABA and anticholinergic, associated with 4) OCS, anti-IgE based treatment, anti-IL5, anti-RIL5, anti-IL4, anti-IL13, thermoplasty.

Results: In January 2023, 214 patients were included. Mean age was 55.1 years old (±16.4). 61.7% were female, 30.0% had a BMI?30 (morbid/severe obesity), 29.3% were previous smokers and 4.8% current smokers. 61.4% had an onset of asthma symptoms after the age of 15 and 21.8% had a history of acute severe asthma. 36.8% had dyspnea (mMRC?2) and 23.8% had chronic cough (>8 weeks). During the 12 months before inclusion, 25.2% had at least 2 exacerbations (having required a general corticotherapy or an increase in ICS treatment). 29.0% had chronic rhinitis, 22.9% gastro-esophageal reflux disease, 19.2% chronic rhinosinusitis, 14.0% anxiety, 13.6% blood hypertension and 13.1% sleep apnea syndrome. Regarding phenotypes: 46.0% were eosinophilic with allergy and 32.1% were eosinophilic without allergy. 135 patients were already on a biotherapy treatment at inclusion and 26 had a biotherapy introduced at inclusion.

Conclusion: These are preliminary results of an observatory of patients followed with severe asthma in the French medical framework.

Sponsors: Bordeaux University Foundation, AstraZeneca, Chiesi, GSK, Novartis, Sanofi.